PTC Therapeutics (NASDAQ:PTCT) Director Sells $1,686,069.52 in Stock

Key Points

• PTC Therapeutics Director Emma Reeve sold 25,562 shares of stock for a total of $1,686,069.52, significantly reducing her ownership by 71.22%.
• PTC Therapeutics reported an earnings per share (EPS) of (-0.83) for the last quarter, surpassing analyst estimates of (-1.07), although revenue was down 4.2% year-over-year.
• The stock has a current market cap of $5.08 billion with a price-to-earnings ratio of 9.17, showing mixed analyst ratings and a target price range between $42.00 and $82.00.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Emma Reeve sold 25,562 shares of the company's stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $65.96, for a total value of $1,686,069.52. Following the completion of the sale, the director owned 10,332 shares in the company, valued at $681,498.72. The trade was a 71.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Emma Reeve also recently made the following trade(s):

• On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The stock was sold at an average price of $59.50, for a total transaction of $934,447.50.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT traded down $0.90 during trading on Tuesday, reaching $63.90. The stock had a trading volume of 1,057,052 shares, compared to its average volume of 1,118,233. PTC Therapeutics, Inc. has a 52 week low of $35.14 and a 52 week high of $67.40. The firm's fifty day moving average is $54.61 and its 200 day moving average is $50.25. The stock has a market cap of $5.08 billion, a price-to-earnings ratio of 9.17 and a beta of 0.55.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.24. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $178.88 million for the quarter, compared to analyst estimates of $173.01 million. During the same quarter in the previous year, the business earned ($1.29) earnings per share. PTC Therapeutics's revenue for the quarter was down 4.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PTCT shares. Royal Bank Of Canada reiterated an "outperform" rating and issued a $63.00 target price (up from $60.00) on shares of PTC Therapeutics in a report on Friday, August 8th. Bank of America lowered their price objective on shares of PTC Therapeutics from $82.00 to $76.00 and set a "buy" rating for the company in a research note on Wednesday, August 20th. Wall Street Zen downgraded shares of PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Barclays raised their price target on shares of PTC Therapeutics from $42.00 to $46.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 29th. Finally, Citigroup lifted their price target on shares of PTC Therapeutics from $40.00 to $50.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, PTC Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $69.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PTCT. Quantbot Technologies LP lifted its stake in shares of PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 551 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 320 shares during the last quarter. GAMMA Investing LLC lifted its position in PTC Therapeutics by 86.3% in the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 441 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in PTC Therapeutics by 247.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 814 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in PTC Therapeutics during the 1st quarter worth approximately $61,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.